Market Place
Sourcing Support
All News #Library
Biotech
Xencor Unveils 2025 Full-Year Financial Results
25 Feb 2026 //
BUSINESSWIRE
Xencor Spotlights 2026 Pipeline Goals
08 Jan 2026 //
BUSINESSWIRE
Xencor Extends US Patent Term For Specific Xtend Antibodies
09 Dec 2025 //
BUSINESSWIRE
Xencor To Participate At Upcoming Investor Conferences
10 Nov 2025 //
BUSINESS WIRE
Xencor Unveils Early Data For Xmab819 In Clear Cell Renal Cell
24 Oct 2025 //
BUSINESSWIRE
Xencor to Discuss Ph1 XmAb819 Results in Renal Cell Carcinoma
21 Oct 2025 //
BUSINESSWIRE
Xencor Presents Ph1 XmAb819 Dose-Escalation Data in ccRCC at AACR
14 Oct 2025 //
BUSINESSWIRE
Xencor Presents Data On XmAb942 For Inflammatory Bowel Diseases
10 Oct 2024 //
BUSINESSWIRE
PESG Report On Silexion`s RNAi Tech For KRAS-Driven Cancers
09 Sep 2024 //
BUSINESSWIRE
Xencor To Regain Global Rights To Bispecific T-Cell Engager Plamotamab
13 Jun 2024 //
NASDAQ
Xencor pulls back from Genentech cancer pact to cut costs
08 Nov 2023 //
FIERCE BIOTECH
Xencor reports data from Phase Ia study of XmAb564 in healthy volunteers
31 May 2023 //
CLINICAL TRIALS ARENA
Xencor to Present Data from Novel XmAb CD28 Bispecific Antibody Programs
14 Mar 2023 //
BUSINESSWIRE
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody
06 Feb 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.